BRCA1/2 Carriers With Breast-Ovarian Double Primary Cancers Versus Ovarian Cancer Alone: Mutation Profiles and Survival Outcomes.
Germline pathogenic variants in BRCA1/2 substantially increase lifetime risks of both breast and ovarian cancers. However, whether specific mutation characteristics predispose carriers to breast-ovarian double primary cancers (DPC) and whether DPC affects ovarian cancer outcomes-particularly in the PARP inhibitor (PARP...